Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.12
+0.26003.79%
Volume:178.46K
Turnover:1.26M
Market Cap:644.81M
PE:-2.95
High:7.20
Open:6.93
Low:6.90
Close:6.86
52wk High:11.25
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.53
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:12.90
PE(LYR):-2.36

Loading ...

Verastem Oncology Announces Two-Year Median Follow-up Data on Avmapki® Fakzynja® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the Sgo 2026 Annual Meeting on Women’s Cancers

THOMSON REUTERS
·
Apr 10

RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)

TIPRANKS
·
Apr 09

GenFleet says China grants breakthrough designation for GFH375 in metastatic pancreatic cancer

Reuters
·
Apr 09

BRIEF-Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 03

Verastem Oncology grants 141,000 restricted stock units to 11 new employees

Reuters
·
Apr 03

Verastem Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 31

Verastem assumed with a Buy at Jefferies

TIPRANKS
·
Mar 30

Verastem management to meet with Cantor

TIPRANKS
·
Mar 27

GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million

Reuters
·
Mar 25

Mizuho Securities Remains a Buy on Verastem (VSTM)

TIPRANKS
·
Mar 20

Verastem Oncology to present VS-7375 data at AACR Annual Meeting 2026

Reuters
·
Mar 18

Verastem to present long-term Phase 2 RAMP 201 data on avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2026

Reuters
·
Mar 18

Verastem Oncology to present AVMAPKI-FAKZYNJA combination data at SGO 2026 Annual Meeting on Women’s Cancers

Reuters
·
Mar 18

Verastem Coverage Assumed by BTIG at Buy

Dow Jones
·
Mar 12

Verastem assumed with a Buy at BTIG

TIPRANKS
·
Mar 12

Undervalued Growth Story in Verastem: Strong AVMAPKI FAKZYNJA Launch and Promising KRASG12D Pipeline Drive Buy Rating and $19 Target

TIPRANKS
·
Mar 12

Verastem Earnings Call: Early Momentum, Long Runway Risks

TIPRANKS
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), Verastem (VSTM) and Align Tech (ALGN)

TIPRANKS
·
Mar 05

Guggenheim Sticks to Their Buy Rating for Verastem (VSTM)

TIPRANKS
·
Mar 05

Verastem: Strong Commercial Uptake and Expanding RAS/MAPK Oncology Pipeline Underpin Buy Rating and $18 Target

TIPRANKS
·
Mar 05